# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0152 |
| Population Package | PP-0152 |
| Title | HDGC Genetic Testing Criteria |
| Version | 1.0.0 |
| Status | PASS |

---

# 1. Content QA

| Criterion | Result |
|---|---|
| Single clinical eligibility question | PASS |
| Personal-history criteria included | PASS |
| Family-history criteria included | PASS |
| Exact age thresholds preserved | PASS |
| Relevant histology preserved | PASS |
| Māori-specific criterion preserved | PASS |
| Cleft lip/palate criteria included | PASS |
| Signet-ring cell carcinoma in situ/pagetoid spread included | PASS |
| Family-degree requirements included | PASS |
| Medical-record verification included | PASS |
| Affected-relative-first strategy included | PASS |
| CDH1 → CTNNA1 pathway included | PASS |
| Criteria-versus-diagnosis distinction included | PASS |
| HDGC-like negative-testing boundary included | PASS |

---

# 2. Clinical QA

| Criterion | Result |
|---|---|
| NCI HDGC PDQ prioritized | PASS |
| IGCLC 2020 criteria represented | PASS |
| Age ≤49 criteria preserved | PASS |
| Age ≤69 criteria preserved | PASS |
| Māori criterion preserved | PASS |
| Diffuse gastric cancer requirement preserved | PASS |
| Lobular breast cancer requirement preserved | PASS |
| Intestinal-type gastric cancer excluded from qualifying HDGC criteria | PASS |
| Non-lobular breast cancer excluded from qualifying HDGC criteria | PASS |
| Family relationship requirements preserved | PASS |
| CDH1 → CTNNA1 pathway preserved | PASS |
| HDGC-like state after negative testing preserved | PASS |
| No variant interpretation added | PASS |
| No unsupported management pathway added | PASS |

---

# 3. Educational QA

| Criterion | Result |
|---|---|
| Plain-language framing | PASS |
| Exact criteria remain identifiable | PASS |
| “Eligibility ≠ diagnosis” clearly stated | PASS |
| Histology importance clearly stated | PASS |
| Medical-record verification explained | PASS |
| Common misconceptions addressed | PASS |
| No alarmist language | PASS |
| No individualized diagnosis | PASS |

---

# 4. Governance QA

| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Gold Specification v1.0 followed | PASS |
| Approved Decision Batch implemented | PASS |
| Scope not reopened after approval | PASS |
| Evidence traceability documented | PASS |
| Knowledge Graph documented | PASS |
| Boundary/overlap declared | PASS |
| Versioning complete | PASS |

---

# 5. Boundary / Overlap QA

## PP-0149 — HDGC

PP-0149 owns:

- syndrome;
- cancer risks;
- management;
- HDGC-like management.

PP-0152 owns:

- clinical eligibility/testing criteria.

**Result: PASS**

## PP-0150 — CDH1

PP-0150 owns:

- CDH1 gene;
- pathogenic variants;
- VUS;
- genotype–phenotype uncertainty.

PP-0152 only hands off the CDH1 testing result.

**Result: PASS**

## PP-0151 — CTNNA1

PP-0151 owns:

- CTNNA1 gene;
- pathogenic variants;
- evidence limitations.

PP-0152 only defines when CTNNA1 testing follows CDH1-negative evaluation.

**Result: PASS**

## PP-0016 — Genetic Testing

PP-0016 owns general testing methodology/process.

PP-0152 owns disease-specific eligibility.

**Result: PASS**

## Variant Interpretation / Genetic Counseling

Detailed interpretation and counseling remain delegated.

**Result: PASS**

---

# 6. Clinical Safety QA

| Safety Item | Result |
|---|---|
| Criteria not presented as diagnosis | PASS |
| No individual cancer-risk calculation | PASS |
| No individual genetic result interpretation | PASS |
| No individualized surgery recommendation | PASS |
| No individualized surveillance schedule | PASS |
| Histology boundaries preserved | PASS |
| Exact thresholds preserved | PASS |
| Negative testing not treated as absolute reassurance | PASS |
| CDH1 management not extrapolated into criteria package | PASS |

---

# 7. Evidence Traceability QA

Primary:

- NCI Hereditary Diffuse Gastric Cancer (PDQ®)
- IGCLC 2020 criteria as summarized by NCI

Supporting:

- NCI Genetics of Gastric Cancer (PDQ®)
- NCI Cancer Genetics Risk Assessment and Counseling (PDQ®)
- relevant project guideline materials
- ESMO-ASCO curriculum where applicable

The canonical eligibility criteria remain source-derived and are not silently broadened or modified.

---

# 8. Scope Integrity QA

### Correctly Included

- exact personal criteria;
- exact family criteria;
- age thresholds;
- histology;
- family relationships;
- pathology verification;
- affected-relative-first testing;
- CDH1 → CTNNA1 pathway;
- criteria-versus-diagnosis distinction.

### Correctly Excluded

- CDH1 variant interpretation;
- CTNNA1 variant interpretation;
- cancer-risk estimation;
- HDGC management;
- RRTG;
- surveillance;
- laboratory methodology;
- detailed counseling.

**Result: PASS**

---

# 9. Knowledge Graph QA

### Clinical decision layer

**PP-0152 — HDGC Genetic Testing Criteria**

↓

### Gene/result layer

**PP-0150 — CDH1**

**PP-0151 — CTNNA1**

↓

### Syndrome/management layer

**PP-0149 — HDGC**

Parallel:

**PP-0016 Genetic Testing**
→ Variant Interpretation
→ Genetic Counseling

Separate:

**PP-0110**
→ **PP-0113**
→ **PP-0114**

**Result: PASS**

---

# 10. Gold Artifact QA

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

---

# 11. Final QA Decision

# PASS

PP-0152 satisfies the locked Gold Population Package requirements.

The package establishes a clean decision-layer architecture:

**PP-0152 = WHO SHOULD BE TESTED?**

→ **PP-0150 / PP-0151 = WHAT DOES THE RESULT MEAN?**

→ **PP-0149 = WHAT DOES HDGC MEAN CLINICALLY / WHAT NEXT?**

The canonical testing criteria are preserved without scope expansion or unsupported reinterpretation.

---

# Final Status

**APPROVED — GOLD / QA PASS**
